Anatomical distribution of bone metastases in stage IV breast cancer: According to histological subtype.

IF 3.2 Q3 ONCOLOGY

World journal of clinical oncology Pub Date : 2025-09-24 DOI:10.5306/wjco.v16.i9.110087

David Shaked Zari, Rostislav Novak, Or Haviv, Itay Ron, Ben Kaplan, Bana Awad, Doron Norman, David Nikomarov

{"title":"Anatomical distribution of bone metastases in stage IV breast cancer: According to histological subtype.","authors":"David Shaked Zari, Rostislav Novak, Or Haviv, Itay Ron, Ben Kaplan, Bana Awad, Doron Norman, David Nikomarov","doi":"10.5306/wjco.v16.i9.110087","DOIUrl":null,"url":null,"abstract":"Background: Bone is the most common site of metastasis in breast cancer, yet limited data exist regarding the precise anatomical distribution of bone metastases by tumor subtype.Aim: To examine the anatomical distribution of the first bone metastases in stage IV breast cancer, stratified by histological subtype. Secondary objectives include analyzing the anatomical distribution of subsequent bone metastases, Metastasis-Free Survival (MFI), Progression-Free Interval (PFI), and overall survival (OS).Methods: A retrospective cohort study was conducted on 107 adult females with stage IV breast cancer and bone metastases between 2013 and 2023. Patients were classified by histological subtype (Luminal A/B, HER2-enriched, and Triple-Negative). First and subsequent bone metastasis locations were identified via computed tomography, positron emission tomography/CT, or magnetic resonance imaging. Survival analyses included MFI, PFI, and OS.Results: Rib metastases were significantly more common in HER2-enriched tumors (80%, P = 0.041), while scapula/clavicle metastases were more prevalent in Triple-Negative cases (37.5%, P = 0.003). Subsequent bone metastases mirrored initial patterns, with pelvic involvement notably higher in HER2-enriched (60%) and luminal B (58%) patients (P = 0.046). No significant differences were found in MFI, PFI, or OS among subtypes. Receptor-based analysis showed no significant variation in bone metastasis locations.Conclusion: Breast cancer subtypes are associated with suggestive bone metastasis patterns-specifically, rib involvement in HER2-enriched and scapula/clavicle in Triple-Negative cases. While anatomical variations exist, they did not translate into differential survival or fracture risk in this cohort.","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 9","pages":"110087"},"PeriodicalIF":3.2000,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476584/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v16.i9.110087","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Bone is the most common site of metastasis in breast cancer, yet limited data exist regarding the precise anatomical distribution of bone metastases by tumor subtype.

Aim: To examine the anatomical distribution of the first bone metastases in stage IV breast cancer, stratified by histological subtype. Secondary objectives include analyzing the anatomical distribution of subsequent bone metastases, Metastasis-Free Survival (MFI), Progression-Free Interval (PFI), and overall survival (OS).

Methods: A retrospective cohort study was conducted on 107 adult females with stage IV breast cancer and bone metastases between 2013 and 2023. Patients were classified by histological subtype (Luminal A/B, HER2-enriched, and Triple-Negative). First and subsequent bone metastasis locations were identified via computed tomography, positron emission tomography/CT, or magnetic resonance imaging. Survival analyses included MFI, PFI, and OS.

Results: Rib metastases were significantly more common in HER2-enriched tumors (80%, P = 0.041), while scapula/clavicle metastases were more prevalent in Triple-Negative cases (37.5%, P = 0.003). Subsequent bone metastases mirrored initial patterns, with pelvic involvement notably higher in HER2-enriched (60%) and luminal B (58%) patients (P = 0.046). No significant differences were found in MFI, PFI, or OS among subtypes. Receptor-based analysis showed no significant variation in bone metastasis locations.

Conclusion: Breast cancer subtypes are associated with suggestive bone metastasis patterns-specifically, rib involvement in HER2-enriched and scapula/clavicle in Triple-Negative cases. While anatomical variations exist, they did not translate into differential survival or fracture risk in this cohort.

查看原文本刊更多论文

IV期乳腺癌骨转移的解剖分布：根据组织学亚型。

背景：骨是乳腺癌最常见的转移部位，但骨转移在肿瘤亚型中的精确解剖分布数据有限。目的：探讨ⅳ期乳腺癌首次骨转移的解剖分布，并按组织学亚型进行分层。次要目的包括分析后续骨转移的解剖分布、无转移生存期（MFI）、无进展间期（PFI）和总生存期（OS）。方法：对2013 - 2023年间107例成年女性IV期乳腺癌合并骨转移患者进行回顾性队列研究。患者按组织学亚型（Luminal A/B、her2富集和三阴性）进行分类。通过计算机断层扫描、正电子发射断层扫描/CT或磁共振成像确定首次和随后的骨转移位置。生存分析包括MFI、PFI和OS。结果：在her2富集的肿瘤中肋骨转移更为常见（80%,P = 0.041），而在三阴性病例中肩胛骨/锁骨转移更为常见（37.5%,P = 0.003）。随后的骨转移反映了最初的模式，在her2富集（60%）和管腔B（58%）的患者中，盆腔转移明显更高（P = 0.046）。各亚型间MFI、PFI或OS无显著差异。基于受体的分析显示骨转移部位无显著差异。结论：乳腺癌亚型与暗示的骨转移模式相关，特别是在her2富集的病例中，肋骨受累，在三阴性病例中肩胛骨/锁骨受累。虽然存在解剖学上的差异，但在该队列中，它们并没有转化为生存或骨折风险的差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World journal of clinical oncology ONCOLOGY-

自引率

0.00%

发文量

585

期刊介绍： The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.